Alkermes plc

NasdaqGS:ALKS 株式レポート

時価総額:US$4.5b

このページの翻訳は実験的なもので、現在開発中です。お待ちしております

Alkermes 過去の業績

過去 基準チェック /56

Alkermesは、平均年間71.2%の収益成長を遂げていますが、 Biotechs業界の収益は、年間 成長しています。収益は、平均年間19.1% 8.1%収益成長率で 成長しています。 Alkermesの自己資本利益率は30%であり、純利益率は25.6%です。

主要情報

71.2%

収益成長率

71.0%

EPS成長率

Biotechs 業界の成長17.0%
収益成長率8.1%
株主資本利益率30.0%
ネット・マージン25.6%
前回の決算情報30 Jun 2024

最近の業績更新

Alkermes' (NASDAQ:ALKS) Solid Profits Have Weak Fundamentals

May 08
Alkermes' (NASDAQ:ALKS) Solid Profits Have Weak Fundamentals

Recent updates

Is Alkermes (NASDAQ:ALKS) A Risky Investment?

Sep 17
Is Alkermes (NASDAQ:ALKS) A Risky Investment?

Alkermes: Fairly Valued After Post-Earnings Bump

Jul 28

Does Alkermes (NASDAQ:ALKS) Deserve A Spot On Your Watchlist?

Jul 26
Does Alkermes (NASDAQ:ALKS) Deserve A Spot On Your Watchlist?

Alkermes plc's (NASDAQ:ALKS) Business And Shares Still Trailing The Industry

Jul 04
Alkermes plc's (NASDAQ:ALKS) Business And Shares Still Trailing The Industry

The Bottom Fishing Club: Alkermes Has Great Value And Safety

May 17

Alkermes' (NASDAQ:ALKS) Solid Profits Have Weak Fundamentals

May 08
Alkermes' (NASDAQ:ALKS) Solid Profits Have Weak Fundamentals

Alkermes: Waking Up Narcolepsy Treatment With Promising Trial Data

Apr 09

Does Alkermes (NASDAQ:ALKS) Have A Healthy Balance Sheet?

Apr 08
Does Alkermes (NASDAQ:ALKS) Have A Healthy Balance Sheet?

Alkermes: Slimmed-Down Pharma Not A Compelling Growth Story Yet

Jan 26

Is Alkermes (NASDAQ:ALKS) Using Too Much Debt?

Nov 01
Is Alkermes (NASDAQ:ALKS) Using Too Much Debt?

Alkermes' (NASDAQ:ALKS) Earnings May Just Be The Starting Point

Nov 01
Alkermes' (NASDAQ:ALKS) Earnings May Just Be The Starting Point

Is Alkermes (NASDAQ:ALKS) Using Debt Sensibly?

Jul 15
Is Alkermes (NASDAQ:ALKS) Using Debt Sensibly?

There Is A Reason Alkermes plc's (NASDAQ:ALKS) Price Is Undemanding

Jun 07
There Is A Reason Alkermes plc's (NASDAQ:ALKS) Price Is Undemanding

Is Alkermes plc (NASDAQ:ALKS) Trading At A 44% Discount?

Apr 10
Is Alkermes plc (NASDAQ:ALKS) Trading At A 44% Discount?

Does Alkermes (NASDAQ:ALKS) Have A Healthy Balance Sheet?

Mar 20
Does Alkermes (NASDAQ:ALKS) Have A Healthy Balance Sheet?

Alkermes upgraded to neutral at BofA on improved risk/reward outlook

Oct 14

Alkermes holder Sarissa Capital says it may look to increase its stake

Oct 07

Alkermes: Nothing Stands Out As Interesting

Sep 26

Health Check: How Prudently Does Alkermes (NASDAQ:ALKS) Use Debt?

Aug 29
Health Check: How Prudently Does Alkermes (NASDAQ:ALKS) Use Debt?

Alkermes initiated at neutral at Piper Sandler as company in transition

Aug 16

Alkermes Q2 2022 Earnings Preview

Jul 26

Is There An Opportunity With Alkermes plc's (NASDAQ:ALKS) 44% Undervaluation?

Jun 27
Is There An Opportunity With Alkermes plc's (NASDAQ:ALKS) 44% Undervaluation?

Alkermes (NASDAQ:ALKS) Has Debt But No Earnings; Should You Worry?

May 16
Alkermes (NASDAQ:ALKS) Has Debt But No Earnings; Should You Worry?

Alkermes: Turning The Tides Towards Profitability

Apr 16

収支内訳

Alkermes の稼ぎ方とお金の使い方。LTMベースの直近の報告された収益に基づく。


収益と収入の歴史

NasdaqGS:ALKS 収益、費用、利益 ( )USD Millions
日付収益収益G+A経費研究開発費
30 Jun 241,508386685249
31 Mar 241,726570713258
31 Dec 231,663519701254
30 Sep 231,591412684198
30 Jun 231,462300669206
31 Mar 231,121-9625229
31 Dec 221,112-33603260
30 Sep 221,132-129627370
30 Jun 221,173-94610387
31 Mar 221,201-62600391
31 Dec 211,17476550291
30 Sep 211,129-92566401
30 Jun 211,100-63558376
31 Mar 211,044-95551373
31 Dec 201,039-111539395
30 Sep 201,171-74566462
30 Jun 201,162-126585477
31 Mar 201,194-139606489
31 Dec 191,171-197599513
30 Sep 191,074-201598412
30 Jun 191,067-183578406
31 Mar 191,092-173561409
31 Dec 181,094-139537415
30 Sep 181,054-139507410
30 Jun 181,023-141477414
31 Mar 18937-152448406
31 Dec 17903-158422413
30 Sep 17842-169417389
30 Jun 17804-196408384
31 Mar 17781-200395382
31 Dec 16746-208383378
30 Sep 16695-257373382
30 Jun 16668-275372376
31 Mar 16624-274347367
31 Dec 15628-227320336
30 Sep 15640-127287317
30 Jun 15648-86249303
31 Mar 15650-36228283
31 Dec 14619-30207265
30 Sep 14598-42201235
30 Jun 14578-10189202
31 Mar 14563-7168172
31 Dec 1359621162153
30 Sep 1357819144140

質の高い収益: ALKSは 高品質の収益 を持っています。

利益率の向上: ALKSの現在の純利益率 (25.6%)は、昨年(20.5%)よりも高くなっています。


フリー・キャッシュフローと収益の比較


過去の収益成長分析

収益動向: ALKS過去 5 年間で収益を上げており、収益は年間69.5%増加しています。

成長の加速: ALKSの過去 1 年間の収益成長率 ( 28.6% ) は、5 年間の平均 ( 年間71.2%を下回っています。

収益対業界: ALKSの過去 1 年間の収益成長率 ( 28.6% ) はBiotechs業界0.5%を上回りました。


株主資本利益率

高いROE: ALKSの 自己資本利益率 ( 30% ) は 高い とみなされます。


総資産利益率


使用総資本利益率


過去の好業績企業の発掘